New Harvard Study: Women on Ozempic-Type Drugs Land Jobs and Partners Faster, Not Raises or Better Marriages

A new working paper out of Stanford is putting numbers on something women have long suspected: losing weight changes how strangers treat you, especially when they're deciding whether to hire you or date you.

Economist Rebecca Diamond published the study, titled "GLP-1-Induced Weight Loss and the Female Obesity Penalty," through the National Bureau of Economic Research. The study has not been peer-reviewed yet. Diamond told Business Insider she started digging into the data after friends who took drugs like Ozempic and Wegovy told her people started treating them differently once they lost weight. She said she expected to find existing research on the economic effects of GLP-1s and was surprised there wasn't any.

What the data shows

Diamond used the Understanding America Study, a panel survey run by the University of Southern California, to compare women who started GLP-1 drugs for weight loss against women who wanted to start but hadn't yet. She excluded diabetic patients, since their drug use is driven by disease, not weight-loss demand, and she focused on women because they use these drugs at higher rates than men.

Among women who weren't employed when the study period began, those on GLP-1s were 27 percentage points more likely to have a job within about 18 months than comparable women who wanted treatment but hadn't started, according to the paper. Among single women, those on GLP-1s were 29 percentage points more likely to be married or living with a partner over the same stretch.

None of that held up for women who already had jobs or relationships. Employed women saw no measurable bump in pay or hours worked. Partnered women were no more or less likely to stay together. The gains showed up only at the moment of a first impression, hiring interviews and new dating.

Confidence or bias? Diamond says it's not that simple

Diamond told Business Insider she's cautious about calling this direct proof of weight discrimination. Health improvements from weight loss could explain part of the employment jump, since obesity-related health issues can limit someone's ability to work. But she found no significant change in depression, loneliness or life satisfaction among the women in the study, according to Business Insider's reporting, which undercuts the theory that this is mostly about improved mental health or better daily functioning.

That detail is important because it means the boost to hiring and dating outcomes showed up without a corresponding boost to how women reported feeling about their lives overall. Something happened in how these women were perceived by strangers, not necessarily in how they felt inside.

Dr. Peter Balazs, a hormone and weight-loss specialist in New York and New Jersey who wasn't involved in the study, told Fox News Digital the pattern says more about societal bias than about the medication. He said his patients often report feeling more confident after weight loss, which can translate into stronger interview performance and networking, and he noted the drugs also carry hormonal effects that can bring metabolic and psychological relief.

Dr. Krishna Vyas, a plastic surgeon at Blechman Plastic Surgery in New York, told Fox News Digital that patients frequently seek body contouring or breast lifts after major GLP-1 weight loss and then re-engage with life more broadly. He called the confidence effect real in his own practice, but pointed out the study found no clear improvement in depression, loneliness or life satisfaction even as marriage and employment numbers climbed.

The fairest read of what this doesn't prove

The study is one working paper, based on a survey dataset, and it hasn't gone through peer review. Diamond herself cautioned against treating it as clean causal proof of hiring or dating discrimination based on weight. Plenty of alternative explanations remain on the table, including that healthier women may simply present differently in an interview room in ways unrelated to bias, or that the sample of women choosing to start GLP-1s differs from those who don't in ways the study can't fully control for.

Still, the design of the comparison—GLP-1 starters versus people who wanted to start but hadn't yet—is built specifically to isolate the effect of weight loss itself rather than just comparing dieters to non-dieters. That's a stronger setup than a lot of pop-science weight loss claims get.

Who can actually afford this

NewBeauty reported that roughly 40% of the GLP-1 users in Diamond's study were paying about $299 a month out of pocket for the drugs. Without insurance coverage, that's over $3,500 a year for a treatment that, according to this research, may be doing more than treating weight. It may be reshaping who gets hired and who finds a partner.

If later, peer-reviewed research confirms Diamond's findings, the open question isn't just about bias in hiring rooms and dating apps. It's about whether an economic advantage this large ends up limited to whoever can afford the monthly bill.